164 related articles for article (PubMed ID: 28430862)
1. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.
Bonnetain F; Borg C; Adams RR; Ajani JA; Benson A; Bleiberg H; Chibaudel B; Diaz-Rubio E; Douillard JY; Fuchs CS; Giantonio BJ; Goldberg R; Heinemann V; Koopman M; Labianca R; Larsen AK; Maughan T; Mitchell E; Peeters M; Punt CJA; Schmoll HJ; Tournigand C; de Gramont A
Ann Oncol; 2017 Sep; 28(9):2077-2085. PubMed ID: 28430862
[TBL] [Abstract][Full Text] [Related]
2. Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer.
Marschner N; Zacharias S; Lordick F; Hegewisch-Becker S; Martens U; Welt A; Hagen V; Gleiber W; Bohnet S; Kruggel L; Dille S; Nusch A; Dörfel S; Decker T; Jänicke M
JAMA Netw Open; 2020 Mar; 3(3):e200643. PubMed ID: 32154886
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer.
Adamowicz K; Saad ED; Jassem J
Cancer Treat Rev; 2016 Nov; 50():194-199. PubMed ID: 27718458
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
[TBL] [Abstract][Full Text] [Related]
6. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer.
Derksen JWG; Kurk SA; Peeters PHM; Dorresteijn B; Jourdan M; van der Velden AMT; Nieboer P; de Jong RS; Honkoop AH; Punt CJA; Koopman M; May AM
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):919-928. PubMed ID: 32107889
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
[TBL] [Abstract][Full Text] [Related]
9. Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
Hamidou Z; Chibaudel B; Hebbar M; Hug de Larauze M; André T; Louvet C; Brusquant D; Garcia-Larnicol ML; de Gramont A; Bonnetain F
PLoS One; 2016; 11(6):e0157067. PubMed ID: 27310205
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review.
Shen C; Tannenbaum D; Horn R; Rogers J; Eng C; Zhou S; Johnson B; Kopetz S; Morris V; Overman M; Parseghian C; Chang GJ; Lopez-Olivo MA; Kanwal R; Ellis LM; Dasari A
JAMA Netw Open; 2022 May; 5(5):e2213588. PubMed ID: 35608860
[TBL] [Abstract][Full Text] [Related]
12. Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point.
Gong J; Wu D; Chuang J; Tuli R; Simard J; Hendifar A
Clin Ther; 2017 Nov; 39(11):2135-2145. PubMed ID: 29079389
[TBL] [Abstract][Full Text] [Related]
13. Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.
Griebsch I; Palmer M; Fayers PM; Ellis S
BMJ Open; 2014 Oct; 4(10):e005762. PubMed ID: 25361836
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer.
Byrne C; Griffin A; Blazeby J; Conroy T; Efficace F
Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S95-104. PubMed ID: 18039559
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
16. [Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis].
Fiteni F; Anota A; Westeel V; Bonnetain F
Bull Cancer; 2015 Apr; 102(4):360-6. PubMed ID: 25799875
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life among patients with esophageal, gastric, and colorectal cancer at Kenyatta National Hospital.
Degu A; Karimi PN; Opanga SA; Nyamu DG
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2038. PubMed ID: 38507287
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis.
Kovic B; Jin X; Kennedy SA; Hylands M; Pedziwiatr M; Kuriyama A; Gomaa H; Lee Y; Katsura M; Tada M; Hong BY; Cho SM; Hong PJ; Yu AM; Sivji Y; Toma A; Xie L; Tsoi L; Waligora M; Prasad M; Bhatnagar N; Thabane L; Brundage M; Guyatt G; Xie F
JAMA Intern Med; 2018 Dec; 178(12):1586-1596. PubMed ID: 30285081
[TBL] [Abstract][Full Text] [Related]
19. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Friedlander M; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Liu J; Mathews C; Selle F; Lortholary A; Lowe ES; Hettle R; Flood E; Parkhomenko E; DiSilvestro P
Lancet Oncol; 2021 May; 22(5):632-642. PubMed ID: 33862001
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
